Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.
DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.
RAW Labs SA is a biomedical-technology development company based at the Biopole of Lausanne, Switzerland. The company focuses on bringing early-stage biomedical technologies, including therapeutics and diagnostics, developed in research institutes to the attention of the pharmaceutical industry. Their portfolio includes critical care products designed to combat sepsis and treat severe bacterial and viral infections. One of their key products, CAL02, is a first-in-class anti-virulence agent aimed at treating severe pneumonia by neutralizing virulence effectors that contribute to organ failure and fatal complications in severe infections. RAW Labs SA's innovative approach and cutting-edge technologies have the potential to significantly impact the field of biomedical research and healthcare.
Melanie Blokesch, Nicolas Jean Philippe Guex, Christian Iseli, Alexandre Lemopoulos, Nina Vesel
Martin Jaggi, Mary-Anne Hartley, Tatjana Chavdarova, Jonathan Dönz